Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
LTR Pharma Unveils Strong SPONTAN Data and Dual US Strategy
LTR Pharma reports SPONTAN PK: 5 mg intranasal Tmax 10 min vs 60 min oral; FDA 505(b)(2) pathway; dual US strategy; $24.1m cash, 2026 milestones
Latest Stories
EVE Health Appoints New CEO to Lead Company Through Next Phase of Growth
EVE Health appoints COO Ben Rohr as new CEO to drive next growth phase and accelerate commercialisation; Damian Wood shifts to regulatory/medical affairs.
Medical Developments International Achieves Positive Cash Flow in Strong Q3 Performance
Medical Developments International posts strong Q3 FY26: revenue $10.5m up 19%, positive cash flow and progress on European paediatric Penthrox approvals.
EBR Systems Wins Fast-Track TGA Review for WiSE CRT Device in Australia
EBR Systems wins TGA Priority Review for WiSE CRT in Australia, slashing evaluation to ~150 days; moves toward ARTG entry and faster patient access.
Noxopharm SOF-SKN Data Shows Prolonged Skin Retention with Minimal Systemic Absorption
Noxopharm's SOF-SKN shows 3.5-day skin retention, minimal systemic absorption in preclinical tests, guiding dosing regimens and regulatory filings.
Vitura Health's Doctors on Demand on Track for Sustained Profitability as Consultations Surpass 1 Million
VIT hits profitability: Doctors on Demand tops 1 million consultations since FY2024; revenue rises 54% to FY2026 Q1-Q3, EBITDA positive at 5%.
Emyria Launches Empax Global Partnership Platform Targeting International Drug Sponsors
Emyria unveils Empax global partnership platform to link international sponsors with its clinical delivery network; Psyence signs for Phase IIb trial.
Global Momentum Continues as Immuron Delivers Double-Digit Q3 Sales Growth in Australia
Immuron delivers double-digit Q3 Travelan growth, led by Australia +15% to AUD 0.9m; Canada doubles; global Q3 sales AUD 1.5m +16%.
BlinkLab Raises A$17.5m to Fund FDA Autism Diagnostic Clearance and Advance ADHD Trials
BlinkLab raises oversubscribed A$17.5m to push FDA autism Dx1 clearance and start ADHD Dx2 trials; Morocco rollout underpins real-world data.
Genetic Signatures Inks 10-Year Danish Supply Deal for GI Screening Technology
GSS signs 10-year Danish deal with Hvidovre Hospital for EasyScreen Pan-Enteric; boosts recurring revenue, EMEA growth; first-year 28k samples from Sept 2026.
Orthocell Secures Access to 221 US Military & VA Medical Centres for Remplir
Orthocell wins access to 221 US DoD/VA centres for Remplir, a major US market expansion as HY26 revenue hits A$6.2m and cash sits at A$49.4m.
Immutep Granted FDA Orphan Drug Designation for Efti in Soft Tissue Sarcoma
Immutep wins FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma, boosting exclusivity and regulatory support as TACTI-004 winds down.